Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Corral-Jaime, J. (Jesús) | - |
dc.creator | Mok, T.S. (Tony S.) | - |
dc.creator | Nakagawa, K. (Kazuhiko) | - |
dc.creator | Rosell, R. (Rafael) | - |
dc.creator | Lee, K.H. (Ki Hyeong) | - |
dc.creator | Migliorino, M.R. (Maria Rita) | - |
dc.creator | Pluzanski, A. (Adam) | - |
dc.creator | Linke, R. (Rolf) | - |
dc.creator | Devgan, G. (Geeta) | - |
dc.creator | Tan, W. (Weiwei) | - |
dc.creator | Quinn, S. (Susan) | - |
dc.creator | Wang, T. (Tao) | - |
dc.creator | Wu, Y.L. (Yi-Long) | - |
dc.date.accessioned | 2021-09-20T09:39:45Z | - |
dc.date.available | 2021-09-20T09:39:45Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Corral-Jaime, J. (Jesús); Mok, T.S. (Tony S.); Nakagawa, K. (Kazuhiko); et al. "Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer". Future Oncology. 15 (24), 2019, 2795 - 2805 | es_ES |
dc.identifier.issn | 1479-6694 | - |
dc.identifier.other | PMID: 31313942 | - |
dc.identifier.uri | https://hdl.handle.net/10171/62028 | - |
dc.description.abstract | Aim: We evaluated reasons for dacomitinib dose reduction (DR) and examined adverse event (AE) incidence, key efficacy end points (progression-free survival [PFS]/overall survival [OS]), and pharmacokinetics in dose-reducing patients in the ARCHER 1050 trial. Patients & methods: Newly diagnosed patients with EGFR mutation-positive, advanced non-small-cell lung cancer received oral dacomitinib (45 mg once-daily [QD]), with stepwise toxicity-managing DR (30 and 15 mg QD) permitted. Results: Skin toxicities (62.7%) were the most common DR-leading AEs. The AE incidence and severity decreased following DRs. Initial plasma dacomitinib exposure (45 mg QD) was generally lower in patients remaining at 45 mg QD compared with dose-reducing patients. Median PFS and OS were similar in all dacomitinib-treated patients and dose-reducing patients. Conclusion: Tolerability-guided dose modifications enabled patients to continue with dacomitinib and benefit from PFS/OS improvement. | es_ES |
dc.description.sponsorship | This study was funded by Pfizer and SFJ Pharmaceuticals | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Future Medicine Ltd | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Materias Investigacion::Ciencias de la Salud::Oncología | es_ES |
dc.subject | EGFR | es_ES |
dc.subject | NSCLC | es_ES |
dc.subject | Dacomitinib | es_ES |
dc.subject | Dose | es_ES |
dc.subject | First-line | es_ES |
dc.title | Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ | es_ES |
dc.identifier.doi | 10.2217/fon-2019-0299 | - |
dadun.citation.endingPage | 2805 | es_ES |
dadun.citation.number | 24 | es_ES |
dadun.citation.publicationName | Future Oncology | es_ES |
dadun.citation.startingPage | 2795 | es_ES |
dadun.citation.volume | 15 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.